Live XELJANZ updates

Live XELJANZ news coverage of developments with the latest updates. Stay on top of latest XELJANZ news stories and find out what just happened, what is going on with XELJANZ. The latest real-time news updates and headlines on XELJANZ
Affordable Drugs Now Accessible for Multiple Cancer, Arthritis Types
XELJANZ PBS-Listed for pcJIA in Patients Aged 2 and Older
Scientists Unveil Harmful Impacts of Immune Hyperactivity in Down Syndrome, Offer Drug Repurposing Solution
April/May 2023 Safety Updates for TGA Products
Janus Kinase Inhibitors: Important Safety Information
Pfizer reports second-quarter 2022 results
U.S. FDA Approves Pfizer's XELJANZ for Treatment of Active Ankylosing Spondylitis
Pfizer's XELJANZ Receives Marketing Authorization in European Union for Treatment of Active Ankylosing Spondylitis
Pfizer reports third-quarter 2021 results
Pfizer's Abrocitinib Receives Positive CHMP Opinion for Treatment of Adults with Moderate to Severe Atopic Dermatitis
XELJANZ Receives Marketing Authorization in European Union for Treatment of Active Polyarticular Juvenile Idiopathic Arthritis
Pfizer reports second-quarter 2021 results
Pfizer Provides Update on U.S. FDA Review of Abrocitinib and XELJANZ Filings
XELJANZ PBS-listed for patients with moderate-to-severe ulcerative colitis
Pfizer reports strong first-quarter 2021 results
Pfizer Announces Extension of Review of New Drug Application of Abrocitinib for Treatment of Moderate to Severe Atopic Dermatitis
Pfizer reports fourth-quarter and full-year 2020 results and releases 5-YEAR pipeline metrics
Pfizer shares co-primary endpoint results
New rheumatoid arthritis treatment added to PBS